Equity / Investment · Africa · Announced 30 Jul 2026
African Development Bank → Biovac
The African Development Bank is lending up to US$15 million to South Africa's Biovac for a new Cape Town multi-vaccine plant, part of an IFC-led financing for capacity of up to 500 million doses a year.
Parties: African Development Bank (AfDB) → Biovac (South Africa)
- Deal type
- Equity / Investment
- Value
- $15m
- Territory
- South Africa (Cape Town), supplying Africa
- Therapeutic area
- Vaccines
- Asset
- Up to US$15M loan toward a new multi-vaccine manufacturing facility in Cape Town (completion targeted 2028)
- Announced
- 30 Jul 2026
Our analysis
Why this matters
The African Development Bank Group has approved a loan of up to US$15 million to Biovac, the Cape Town-based vaccine company, toward a new multi-vaccine manufacturing facility due to be completed by 2028. The AfDB joins a consortium of development finance institutions led by the International Finance Corporation.
Africa makes only a small fraction of the vaccines it uses, and the African Union's goal is to make most of them locally by 2040. Biovac's plan — up to 500 million doses a year, starting with oral cholera vaccine and adding inactivated polio, pneumococcal and meningitis vaccines — is one of the few projects on the continent with both technology partners and a financing stack in place.
The full analysis is free to read with a work email on this page.
Source: African Trade Chamber